Abstract:The new coronavirus disease, COVID-19, caused by SARS-CoV-2, continues to affect the world and after more than two years of the pandemic, approximately half a billion people are reported to have been infected. Due to its high contagiousness, our life has changed dramatically, with consequences that remain to be seen. To prevent the transmission of the virus, it is crucial to diagnose COVID-19 accurately, such that the infected cases can be rapidly identified and managed. Currently, the gold standard of testing is polymerase chain reaction (PCR), which provides the highest accuracy. However, the reliance on centralized rapid testing modalities throughout the COVID-19 pandemic has made access to timely diagnosis inconsistent and inefficient. Recent advancements in photonic biosensors with respect to cost-effectiveness, analytical performance, and portability have shown the potential for such platforms to enable the delivery of preventative and diagnostic care beyond clinics and into point-of-need (PON) settings. Herein, we review photonic technologies that have become commercially relevant throughout the COVID-19 pandemic, as well as emerging research in the field of photonic biosensors, shedding light on prospective technologies for responding to future health outbreaks. Therefore, in this article, we provide a review of recent progress and challenges of photonic biosensors that are developed for the testing of COVID-19, consisting of their working fundamentals and implementation for COVID-19 testing in practice with emphasis on the challenges that are faced in different development stages towards commercialization. In addition, we also present the characteristics of a biosensor both from technical and clinical perspectives. We present an estimate of the impact of testing on disease burden (in terms of Disability-Adjusted Life Years (DALYs), Quality Adjusted Life Years (QALYs), and Quality-Adjusted Life Days (QALDs)) and how improvements in cost can lower the economic impact and lead to reduced or averted DALYs. While COVID19 is the main focus of these technologies, similar concepts and approaches can be used and developed for future outbreaks of other infectious diseases.

On‐Chip Optical Detection of Viruses: A Review

Emerging nanophotonic biosensor technologies for virus detection

Recent advances in nucleic acid analysis and detection with microfluidic and nanofluidics

Progress and Outlooks in Designing Photonic Biosensor for Virus Detection

Point-of-care diagnostics for infectious diseases: From methods to devices

Recent Advances of Representative Optical Biosensors for Rapid and Sensitive Diagnostics of SARS-CoV-2

Fast Accurate Point of Care COVID-19 Pandemic Diagnosis Enabled Through Advanced Lab-on-a-Chip Optical Biosensors: Opportunities and Challenges

Optical Biosensors for Virus Detection: Prospects for SARS‐CoV‐2/COVID‐19

Trapping and Detection of Single Viruses in an Optofluidic Chip

Progress and Challenges of Point-of-Need Photonic Biosensors for the Diagnosis of COVID-19 Infections and Immunity

Recent advances in point-of-care testing of COVID-19

Microfluidic chip and isothermal amplification technologies for the detection of pathogenic nucleic acid

Recent Advances in DNA Nanotechnology‐Based Sensing Platforms for Rapid Virus Detection

Advanced “lab-on-a-chip” to detect viruses – Current challenges and future perspectives

Fast, accurate, point-of-care COVID-19 pandemic diagnosis enabled through advanced lab-on-chip optical biosensors: Opportunities and challenges

Recent advancements in nucleic acid detection with microfluidic chip for molecular diagnostics

Microfluidics-Based Point-of-Care Testing (POCT) Devices in Dealing with Waves of COVID-19 Pandemic: The Emerging Solution

Recent Progress on Rapid Diagnosis of COVID-19 by Point-of-care Testing Platforms.

Facile biosensors for rapid detection of COVID-19

Micro/nano biomedical devices for point-of-care diagnosis of infectious respiratory diseases

A fiber optic–nanophotonic approach to the detection of antibodies and viral particles of COVID-19